WINNIPEG, MANITOBA -- (Marketwire) -- 02/19/13 -- Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today the appointment of two key members to its international market development team, to help guide the Company's efforts in developing international markets for its PreVu® Non-Invasive Skin Cholesterol technology. Miraculins has engaged Mr. Charles G. Nell and Mr. Paul Mordente, both proven pharmaceutical sales executives and business development leaders, who will focus their efforts on the United States and the United Kingdom/European Union, respectively, with the primary goal of introducing PreVu into the retail pharmacy segments in those territories.
Additional goals of the international market development team are to support the Company's efforts in general market development activities in the U.S. and UK/EU including identifying and evaluating potential distribution partners, evaluating distribution alternatives and facilitating meetings with key industry members with the objective of establishing and ultimately growing sales in international markets across multiple segments.
Charles G. Nell has held a number of strategic sales and marketing positions, with a focus on market expansion, throughout his career. Mr. Nell served at a Vice President level for over ten years with AmerisourceBergen, the largest pharmaceutical distributor in the United States, where he was instrumental in designing and implementing an innovative selling program that identified additional revenue opportunities for the company which soon became an industry standard. Mr. Nell was also responsible for sales expansion along with new business growth within the National and Regional pharmacy chain portfolio in the United States. Mr. Nell has most recently been working as the Vice President of Sales and Business Development - U.S. for Pear Healthcare Solutions, Miraculins' exclusive distribution partner for the Canadian retail pharmacy market.
Paul Mordente brings over 25 years of sales, marketing and management experience, including a series of senior roles in building the European operations for LifeScan Inc., a Johnson & Johnson Company focused on blood glucose and diabetes monitoring systems. Mr. Mordente currently serves as the Managing Director of Amalfi Business Consultants, a United Kingdom based firm that is experienced in market planning and execution strategy for pharmaceutical and medical device products and which has represented major global companies such as GSK, Johnson & Johnson and Inverness Medical (Alere) on various international projects.
"The introduction of PreVu into both the United States and the UK/European Union pharmacy markets, are two of our primary objectives for 2013, and these appointments are an important step towards achieving those milestones," stated Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc. "I am very pleased to have both Charles and Paul on the Miraculins team and feel confident about our ability to execute our business plan in these important international markets."
Most Popular Stories
- SpaceX's Satellite Launch Is 'Game-Changer'
- Reid Confident Congress to Pass Immigration Bill
- Maui Visitor Killed in Shark Attack
- Donors Abandon GOP Over Gun Stance
- Mexico: 'Extremely Dangerous' Radioactive Material Stolen
- CEOs More Optimistic About Economy, Hiring
- Climate Change Early Warning System Urged
- Private Sector Employment Surges by 215,000 Jobs
- Calif. Likes Christie, Says Tea Party's a Drag
- Newtown 911 Tapes Being Released Today